


Understanding the Insurance Reauthorization Process

This guide provides an overview of the potential reauthorization process for DAWNZERA™ (donidalorsen) and can help you understand

- Support available from Ionis Every Step™
- Criteria and documentation that may be required by the insurance plan
- Potential reasons for denials and how to initiate an appeal
- Next steps after reauthorization approval

Your Patient Started DAWNZERA— What’s Next?



Overview of the reauthorization process

Insurance plans often require **reauthorization** for specialty medications, like DAWNZERA, to determine if they will continue to cover the patient’s treatment (similar to the initial approval process).

Reauthorization is typically required **6 to 12 months** after the initial exception or prior authorization approval, however, this varies by plan

Reauthorization timelines are put in place so that the insurance plan can **assess treatment effectiveness, continued medical necessity, and appropriate use**

Insurance plan timelines and requirements can be found on the **insurance plan’s website** and vary by plan



Confirm the length of initial approval and begin the reauthorization process 60 days before the end of this timeframe

Support for the Reauthorization Process



Ionis Every Step is committed to helping your appropriate patient continue treatment with DAWNZERA



DAWNZERA Direct

- This online companion allows you to stay connected to your patient’s treatment journey with DAWNZERA
- Your patient can provide you with the information logged (eg, doses of DAWNZERA taken) to help support reauthorization requests
- Encourage your patient to reach out to their Patient Education Manager to sign up for DAWNZERA Direct

Connect with your Account Specialist to gain access to DAWNZERA Direct



DAWNZERA AuthASSIST

- Our team is committed to providing you with comprehensive reauthorization support to help you get ahead of the submission
- Support from DAWNZERA AuthASSIST may help reduce delays in your patient’s treatment and ensure timely delivery of their next dose

Call Ionis Every Step at 1-844-444-4305, Monday to Friday, 8 AM to 8 PM ET, for more support helping your patients continue treatment

Submitting a Reauthorization

Understanding the required plan-specific criteria and processes early can help you navigate reauthorization and may help avoid delays in continuing treatment.

1. Plan

The criteria below represent potential reauthorization criteria that may be required by insurance plans for medications like DAWNZERA. Keep in mind that criteria vary from plan to plan.

Examples of reauthorization criteria	Examples of documentation to support criteria
Documented clinical response to treatment	- Lab results before treatment with DAWNZERA - Medical records or chart notes describing frequency, severity, and duration of attacks before and during treatment with DAWNZERA
Decrease in use of on-demand therapy	Prescription refill history for acute therapy
Adherence to therapy	Prescription refill history for DAWNZERA

2. Prepare

-  **Target** a date before the end of the initial approval period to begin preparing your request (eg, 60 days in advance)
-  **Work** with Ionis Every Step to understand plan-specific reauthorization requirements, forms, and timelines for submission
-  **Collect** information from your patient regularly (eg, at baseline, during treatment) to help support medical necessity for continued treatment
-  **Encourage** patients to use DAWNZERA Direct to track their DAWNZERA treatment journey

3. Submit

-  **Confirm** the insurance plan's method for submitting the reauthorization request
-  **Submit** electronically or call the insurance plan

Addressing Reauthorization Denials



Insurance plans may deny reauthorization requests for a few reasons. The considerations below may help avoid unnecessary denials.

 Potential reason	 Considerations
Patient's insurance plan changes formulary tier for DAWNZERA	Confirm the insurance plan's coverage policy prior to requesting reauthorization and if there is a process in place to request a tier exception
Patient's insurance plan has restrictions on the quantity or number of refills allowed in a specified timeframe	Confirm quantity limit requirements prior to requesting reauthorization and double check that the correct amount was requested
No documentation of baseline characteristics supporting continued need for treatment	Ensure documentation of baseline attack characteristics is included with the reauthorization request
No documentation of frequency/severity of attacks while on treatment (eg, via patient tracker/diary)	Ensure documentation of any attacks while on DAWNZERA is included with the reauthorization request

Next steps after a reauthorization denial

-  **Review** the communication from the insurance plan to understand the reason for denial and the plan's specific next steps
-  **Learn** more about why the reauthorization was denied by scheduling a peer-to-peer review with the insurance plan
-  **Draft a Letter of Appeal** to provide additional rationale for continuing treatment and include relevant documentation

What's Next After Reauthorization Is Approved?

A reauthorization approval means that the insurance plan determined DAWNZERA is still medically necessary, and your patient will be **covered for another approval period** (eg, 6 or 12 months). Consider these next steps after receiving an approval:



Follow up with your patient to confirm that they received their next shipment of DAWNZERA



Target a date before the end of the renewed approval period to begin preparing your next reauthorization request (eg, 60 days in advance)



Remind your patient to keep using DAWNZERA Direct to track their treatment journey with DAWNZERA



Continue collecting information from your patient regularly to support future reauthorization requests

Helpful Notes and Reminders

Use the space below to note any important reminders for the reauthorization process (eg, timelines and specific criteria for insurance plans that cover your patients on DAWNZERA).

Ionis Every Step can help your patients continue to follow your prescribed treatment plan with DAWNZERA. Call 1-844-444-4305 for more support



Ionis Every Step can help your office navigate the reauthorization process



Call 1-844-444-4305, Monday to Friday, 8 AM to 8 PM ET, for more support



©2025 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
All product names, logos, and brands are property of their respective owners.
All rights reserved. US-DONI-2500086 v1.0 08/2025

DAWNZERA
(donidalorsen) 80 mg/0.8 mL
injection